Cocrystal Pharma adds Carol Brosgart, MD to board of directors
The antiviral biotech named the physician-scientist and veteran biopharma board member to its board effective August 12, 2026.
Cocrystal Pharma, Inc. announced that on August 12, 2026, the Board of Directors of Cocrystal Pharma, Inc. appointed Carol L. Brosgart as a director of the Company, effective immediately.1 The company disclosed the appointment in an 8-K filing, and followed with a separate 8-K and press release on August 17, 2026 providing further detail.
According to the filing, there are no arrangements or understandings between Brosgart and any other persons regarding her selection as director, no family relationships with other directors or officers, and no related party transactions requiring disclosure under Item 404(a) of Regulation S-K.1
The press release describes Brosgart as bringing several decades of experience in antiviral therapy, epidemiology, and biopharma advisory.2 Chairman Roger Kornberg said her insights will be relevant as the company works to advance the clinical development of CDI-988 for norovirus, as well as the broader development of Cocrystal's antiviral pipeline.2
Her background includes work at Gilead Sciences, where she spent more than a decade and played a role in the development and regulatory approval of the antiviral therapies Viread and Hepsera.2 She also was the founding Medical Director of the East Bay AIDS Center at Alta Bates Medical Center in Berkeley, California.2
Brosgart currently holds several board and advisory roles. She is a member of the Board of Directors of the Hepatitis B Foundation, previously co-chaired the National Task Force on Hepatitis B, was a Senior Advisor on Science and Policy to the CDC's Division of Viral Hepatitis and the Viral Hepatitis Action Coalition at the CDC Foundation, and currently sits on the boards of Galmed Pharmaceuticals, Eradivir Biotech, and Merlin Biotech, with prior board positions at Abivax, Mirum Pharmaceuticals, Tobira Therapeutics and Juvaris.2 She earned her medical degree from the University of California, San Francisco School of Medicine, where she currently serves as a Clinical Professor of Medicine, Biostatistics and Epidemiology.2
Written by readthrough’s AI from the linked primary sources and fact-checked against them automatically before publishing. Not investment advice.